Insmed Gestion
Gestion contrôle des critères 3/4
Le PDG Insmed est Will Lewis, nommé en Sep2012, a un mandat de 13.75 ans. La rémunération annuelle totale est $ 14.47M, composée du salaire de 5.9% et des bonus 94.1%, y compris les actions et options de la société. détient directement 0.23% des actions de la société, d'une valeur de $ 47.02M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 6.8 ans et 8.1 ans.
Informations clés
Will Lewis
Directeur général
US$14.5m
Rémunération totale
| Pourcentage du salaire du PDG | 5.91% |
| Durée du mandat du directeur général | 13.8yrs |
| Propriété du PDG | 0.2% |
| Durée moyenne d'occupation des postes de direction | 6.8yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 8.1yrs |
Mises à jour récentes de la gestion
Recent updates
Mise à jour du récit • Jun 02
INSM: 2026 Respiratory Launch Execution Will Drive Bronchiectasis Leadership Debate
Analysts have trimmed their average price target on Insmed to about $200 from $212.50, reflecting updated Q1 models that factor in recent competitive developments and refreshed Brinsupri expectations, while still largely maintaining constructive views on the stock. Analyst Commentary Street research around Insmed has been active, with multiple firms adjusting price targets and ratings following Q1 results, clinical updates and early feedback on Brinsupri.
Nouveau récit • May 28
Pulmonary Disease Headwinds Will Test This Respiratory Franchise Before Long Term Potential Emerges
Catalysts About Insmed Insmed focuses on therapies for serious respiratory and rare diseases, including bronchiectasis, NTM MAC lung infection and pulmonary hypertension indications. What are the underlying business or industry changes driving this perspective?
Nouveau récit • May 13
Future Respiratory Breakthroughs And Pipeline Expansion Will Transform Long Term Earnings Power
Catalysts About Insmed Insmed focuses on developing and commercializing therapies for serious respiratory and rare diseases. What are the underlying business or industry changes driving this perspective?Article d’analyse • May 11
Insmed Incorporated (NASDAQ:INSM) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Shareholders in Insmed Incorporated ( NASDAQ:INSM ) had a terrible week, as shares crashed 28% to US$101 in the week...Mise à jour du récit • Apr 22
INSM: 2026 Respiratory Launch Execution Will Shape Bronchiectasis Leadership Trajectory
Insmed's updated analyst price target edges down by about $2 to $212.50, as analysts weigh slightly higher discount rate assumptions against continued strong expectations for Brinsupri and the broader respiratory pipeline, as reflected in a series of recent target revisions and new bullish initiations. Analyst Commentary Recent research has been active around Insmed, with several firms updating targets and views following Brinsupri launch commentary, ENCORE data, and management guidance.Mise à jour du récit • Apr 06
INSM: 2026 Respiratory Launch Execution Will Drive Bronchiectasis Market Expansion
Analysts have nudged Insmed's fair value estimate higher to $214.32, reflecting a series of recent price target increases that are tied to confidence in the Brinsupri launch, an expanded bronchiectasis opportunity, and updated Street research on the company's broader respiratory portfolio. Analyst Commentary Recent Street research around Insmed clusters around a few common themes, with most attention on Brinsupri execution, the bronchiectasis market opportunity, and updated revenue guidance through 2026.Seeking Alpha • Apr 01
Insmed: The Pipeline Is Catching Up To The Valuation
Summary Insmed remains a Buy, with enterprise value near $30B and robust growth driven by Brinsupri and pipeline assets. Brinsupri's launch exceeded expectations, with Q4 revenues of $144.6M and management guiding for $1B in 2026 sales. TPIP offers differentiation in PAH/PH-ILD with once-daily dosing and encouraging Phase 2b data, supporting a $3B rNPV estimate. Despite ongoing cash burn, INSM's strong balance sheet and strategic R&D investments position it for continued upside and potential acquisition interest. Read the full article on Seeking AlphaMise à jour du récit • Mar 20
INSM: 2026 Respiratory Revenue Milestone And Market Expansion Will Drive Platform Potential
Analysts have made a modest upward adjustment to the Insmed price target, increasing the estimated fair value from about $212.53 to $213. They cite renewed confidence in Brinsupri's launch potential, reinforced 2026 guidance and broader bronchiectasis market opportunities highlighted across recent research from Jefferies, BofA, Mizuho, Morgan Stanley, Wells Fargo, Stifel, UBS, Barclays, Roth and RBC.Mise à jour du récit • Mar 05
INSM: Brinsupri Launch And 2026 Revenue Milestone Will Support Future Platform Expansion
Analysts have trimmed their average price target on Insmed by a few dollars to about $213, as slightly higher discount rates and more measured revenue and margin assumptions offset continued optimism around the Brinsupri launch and its longer term market opportunity. Analyst Commentary Recent Street commentary on Insmed clusters around the same core themes, with valuation tweaks mainly driven by updated assumptions on Brinsupri, management's long range guidance, and broader biotech sector conditions.Mise à jour du récit • Feb 18
INSM: European Respiratory Approval And NASDAQ Inclusion Will Support Future Platform Expansion
Narrative Update: Insmed Analyst Price Target Shift Insmed's blended analyst price target edges down by about $1 to roughly $214 as analysts balance slightly lower long term growth and P/E assumptions with ongoing support for the pipeline and recent target changes across the Street. Analyst Commentary Street research on Insmed over recent months shows a cluster of bullish initiations and target moves, with a few more cautious tweaks at the margin.Mise à jour du récit • Feb 04
INSM: European Respiratory Progress And NASDAQ Inclusion Will Support Future Platform Expansion
Analysts have nudged their blended price target for Insmed higher to about $215 per share, reflecting slightly stronger revenue and margin assumptions and a lower future P/E following recent initiation and target updates across the Street. Analyst Commentary Bullish analysts are leaning into Insmed's updated pricing and P/E framework, pointing to specific pipeline and sector factors that they see as supporting the higher blended price target, while more cautious voices are focusing on funding needs and competitive pressures across biotech.Mise à jour du récit • Jan 20
INSM: European Respiratory Portfolio Momentum Will Support Future Platform Expansion
Analysts have nudged their blended price expectations for Insmed slightly lower, trimming the implied fair value by about US$1.60 to reflect modestly higher discount rates, even as they factor in stronger projected revenue growth, wider profit margins and a lower assumed future P/E multiple. This view is supported by recent research highlighting both sector wide M&A potential and company specific drivers such as Brinsupri's EC approval, Q3 execution and anticipated respiratory portfolio expansion.Mise à jour du récit • Jan 06
INSM: European Bronchiectasis Approval Will Support Future Respiratory Platform Expansion
Analysts now place Insmed's blended price target at about US$215.56, edging up from roughly US$214.78 as they factor in recent target moves across the Street tied to Brinsupri's EC approval, Q3 execution, and the broader biotech funding backdrop. Analyst Commentary Bullish Takeaways Bullish analysts highlight Brinsupri's formal EC approval for certain non cystic fibrosis bronchiectasis patients and planned early 2026 access, which they see as an important driver underpinning higher valuation targets above US$210.Mise à jour du récit • Dec 22
INSM: European Bronchiectasis Launch Will Drive Future Respiratory Platform Upside
Insmed's analyst price target has been lifted by about $8 to roughly $215, as analysts factor in strong Brinsupri momentum, expanding indications, and solid execution across the broader respiratory pipeline. Analyst Commentary Bullish analysts continue to lift their models as Brinsupri's early momentum and label breadth in non cystic fibrosis bronchiectasis reshape expectations for Insmed's long term revenue trajectory and margin expansion.Mise à jour du récit • Dec 08
INSM: Respiratory Portfolio Execution And European Expansion Will Shape Future Outlook
Analysts have modestly lifted their price target on Insmed from $214 to $223, reflecting stronger confidence in Brinsupri's European launch trajectory, the expansion of non cystic fibrosis bronchiectasis indications, and continued evidence of robust execution across the broader respiratory portfolio. Analyst Commentary Recent Street research continues to skew positive, with multiple bullish analysts lifting price targets in response to stronger than expected commercial execution and an expanding opportunity set around Brinsupri and the broader respiratory platform.Mise à jour du récit • Nov 24
INSM: Commercial Execution And Pipeline Progress Will Shape Balanced Outlook
Analysts have raised their price target for Insmed from $204.50 to $214.12, citing strong commercial performance, positive product launches, and greater confidence in the company's revenue growth prospects, even as profitability and valuation metrics continue to evolve. Analyst Commentary Analysts covering Insmed have provided a range of perspectives following recent product launches and clinical updates.Mise à jour du récit • Nov 01
INSM: 2025 Launch Will Drive Respiratory Platform Expansion Amid Elevated Expectations
Insmed's analyst price target has climbed significantly, rising by more than $30 to $204.50. Analysts cite stronger pipeline execution, improving profit margins, and expanding growth opportunities across its lead programs as key reasons for the increase.Mise à jour du récit • Oct 17
Brensocatib's 2025 Launch Will Transform Bronchiectasis Care
Analysts have raised their price target for Insmed, increasing fair value from $164.41 to $172.59. This adjustment is driven by anticipation of broader Brinsupri uptake, pipeline advancements, and improved sentiment following positive clinical and commercial updates.Mise à jour du récit • Oct 03
Brensocatib's 2025 Launch Will Transform Bronchiectasis Care
Insmed's analyst price target has increased by over $6 to $164.41, as analysts cite stronger revenue growth projections and recent clinical and commercialization achievements as key catalysts for the upward revision. Analyst Commentary Recent analyst activity around Insmed highlights a dynamic mix of optimism and caution, reflecting both the company's clinical progress and commercial prospects.Mise à jour du récit • Sep 07
Brensocatib's 2025 Launch Will Transform Bronchiectasis Care
Insmed’s consensus price target has increased to $158.00, reflecting analyst optimism around Brinsupri’s broad FDA approval, strong initial commercial outlook, advancing pipeline assets, and positive clinical data, despite some valuation concerns following the recent price appreciation. Analyst Commentary Bullish analysts are raising price targets following the FDA approval of Brinsupri (brensocatib) for non-cystic fibrosis bronchiectasis, highlighting a broad label, no major safety warnings, inclusion of FEV1 efficacy data, and a high launch price as key upside surprises that position the therapy for multi-billion dollar opportunities.Mise à jour du récit • Aug 23
Brensocatib's 2025 Launch Will Transform Bronchiectasis Care
Insmed’s consensus price target has surged to $148.44, driven by the FDA approval and strong commercial prospects for Brinsupri, expanded pipeline potential, and robust Phase 2 results for TPIP—underscoring significant upward revisions in revenue and profit expectations. Analyst Commentary Bullish analysts are raising price targets following FDA approval of Brinsupri as the first therapy for non-cystic fibrosis bronchiectasis, citing a broad label with both doses approved, clean safety profile, and inclusion of favorable FEV1 and secondary endpoint data in prescribing information.Mise à jour du récit • Aug 08
Brensocatib's 2025 Launch Will Transform Bronchiectasis Care
Despite a sharply higher future P/E and a substantial decline in net profit margin, analysts have aggressively raised Insmed’s price target from $68.64 to $120.12. What's in the News Insmed reported positive topline Phase 2b results for treprostinil palmitil inhalation powder (TPIP) in pulmonary arterial hypertension, meeting primary and all secondary endpoints.Article d’analyse • Jun 11
Insmed Incorporated's (NASDAQ:INSM) Shares Climb 40% But Its Business Is Yet to Catch Up
Insmed Incorporated ( NASDAQ:INSM ) shareholders would be excited to see that the share price has had a great month...Seeking Alpha • Apr 25
Insmed: Poised For Transformation Beyond ARIKAYCE
Summary Insmed's future hinges on the development and launch of its pipeline, particularly brensocatib, despite current financial losses due to strategic investments. Brensocatib shows promising Phase 3 results for non-cystic fibrosis bronchiectasis, with a potential FDA approval by August 2025, highlighting a significant market opportunity. Insmed's diversified pipeline, including TPIP and INS1201, reduces reliance on a single product and enhances long-term growth prospects. Despite financial risks, INSM's $1.4 billion cash reserve and potential multi-billion dollar market opportunities make it a compelling investment for those with a high-risk tolerance. Read the full article on Seeking Alpha
Nouveau récit • Mar 19
Brensocatib's 2025 Launch Will Transform Bronchiectasis Care
Anticipated U.S. and international launches of brensocatib are key catalysts for significant revenue growth and new market penetration.Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$1b |
| Dec 31 2025 | US$14m | US$855k | -US$1b |
| Sep 30 2025 | n/a | n/a | -US$1b |
| Jun 30 2025 | n/a | n/a | -US$1b |
| Mar 31 2025 | n/a | n/a | -US$1b |
| Dec 31 2024 | US$11m | US$810k | -US$914m |
| Sep 30 2024 | n/a | n/a | -US$864m |
| Jun 30 2024 | n/a | n/a | -US$803m |
| Mar 31 2024 | n/a | n/a | -US$747m |
| Dec 31 2023 | US$10m | US$780k | -US$750m |
| Sep 30 2023 | n/a | n/a | -US$724m |
| Jun 30 2023 | n/a | n/a | -US$696m |
| Mar 31 2023 | n/a | n/a | -US$547m |
| Dec 31 2022 | US$8m | US$735k | -US$482m |
| Sep 30 2022 | n/a | n/a | -US$434m |
| Jun 30 2022 | n/a | n/a | -US$416m |
| Mar 31 2022 | n/a | n/a | -US$438m |
| Dec 31 2021 | US$7m | US$710k | -US$435m |
| Sep 30 2021 | n/a | n/a | -US$424m |
| Jun 30 2021 | n/a | n/a | -US$375m |
| Mar 31 2021 | n/a | n/a | -US$319m |
| Dec 31 2020 | US$6m | US$660k | -US$294m |
| Sep 30 2020 | n/a | n/a | -US$245m |
| Jun 30 2020 | n/a | n/a | -US$242m |
| Mar 31 2020 | n/a | n/a | -US$247m |
| Dec 31 2019 | US$7m | US$641k | -US$254m |
Rémunération vs marché: La rémunération totale de Will ($USD 14.47M ) est dans la moyenne des entreprises de taille similaire sur le marché US ($USD 14.81M ).
Rémunération et revenus: La rémunération de Will a augmenté alors que l'entreprise n'est pas rentable.
PDG
Will Lewis (57 yo)
13.8yrs
Titularisation
US$14,467,393
Compensation
Mr. William H. Lewis, J.D. M.B.A. also known as Will, serves as an Independent Chairman of Board of Directors of NewAmsterdam Pharma Company N.V. from January 2024. He has been Chief Executive Officer and...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| President | 13.8yrs | US$14.47m | 0.23% $ 47.0m | |
| Chief Financial Officer | 6.4yrs | US$4.62m | 0.011% $ 2.2m | |
| Chief Operating Officer | 6.6yrs | US$4.69m | 0.027% $ 5.6m | |
| Chief Legal Officer & Corporate Secretary | 4.9yrs | US$4.14m | 0.018% $ 3.7m | |
| Chief Medical Officer | 6.5yrs | US$4.72m | 0.028% $ 5.7m | |
| Chief Scientific Officer | no data | pas de données | pas de données | |
| Vice President of Investor Relations | no data | pas de données | pas de données | |
| Chief Compliance Officer | no data | pas de données | pas de données | |
| Vice President of Corporate Communications | no data | pas de données | pas de données | |
| Chief People Strategy Officer | 13.4yrs | US$2.66m | 0.019% $ 3.9m | |
| Chief Product Strategy Officer | 9.1yrs | US$1.69m | pas de données | |
| GM & Head of Europe | 7yrs | pas de données | pas de données |
6.8yrs
Durée moyenne de l'emploi
57yo
Âge moyen
Gestion expérimentée: L'équipe dirigeante de INSM est chevronnée et expérimentée (6.8 années d'ancienneté moyenne).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| President | 13.8yrs | US$14.47m | 0.23% $ 47.0m | |
| Independent Director | 25.1yrs | US$425.00k | 0.12% $ 25.4m | |
| Lead Independent Director | 12.1yrs | US$465.00k | 0.056% $ 11.4m | |
| Independent Director | 6.6yrs | US$425.00k | 0.032% $ 6.6m | |
| Independent Director | 7.6yrs | US$432.86k | 0.027% $ 5.5m | |
| Independent Director | 8.1yrs | US$425.00k | 0.025% $ 5.1m | |
| Independent Director | 6.2yrs | US$427.50k | 0.029% $ 6.0m |
8.1yrs
Durée moyenne de l'emploi
62yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de INSM sont considérés comme expérimentés (ancienneté moyenne 8.1 ans).
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/06/09 15:12 |
| Cours de l'action en fin de journée | 2026/06/09 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Insmed Incorporated est couverte par 42 analystes. 20 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Neena Bitritto-Garg | Baird |
| Eliana Merle | Barclays |
| Anita Dushyanth | Berenberg |